| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHSURG.1985.01390320023003 |
| P698 | PubMed publication ID | 4015380 |
| P2093 | author name string | Ellenberg SS | |
| Kalser MH | |||
| P433 | issue | 8 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 899-903 | |
| P577 | publication date | 1985-08-01 | |
| P1433 | published in | Archives of Surgery | Q15764793 |
| P1476 | title | Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection | |
| P478 | volume | 120 |
| Q79369906 | 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience |
| Q72425651 | 5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. GLISP (Gruppo Ligure Studio Pancreas) |
| Q43816568 | 5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer |
| Q30238706 | A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review |
| Q41276687 | A Tale of Two Cities: Reconsidering Adjuvant Radiation in Pancreatic Cancer Care |
| Q28077111 | A current perspective on stereotactic body radiation therapy for pancreatic cancer |
| Q39087110 | A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study |
| Q34904065 | A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation |
| Q47731653 | A look at the progress of treating pancreatic cancer over the past 20 years |
| Q41598569 | A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma |
| Q90609154 | A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection |
| Q84445743 | A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma |
| Q33928176 | A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database |
| Q40639767 | A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics |
| Q34335982 | A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. |
| Q34617610 | A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma |
| Q33332875 | A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer |
| Q46934864 | A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract |
| Q33347128 | A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer |
| Q73153275 | A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer |
| Q35761097 | A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma |
| Q64119462 | A phase II study of intraoperative radiotherapy using a low-energy x-ray source for resectable pancreatic cancer: a study protocol |
| Q42506592 | A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer |
| Q72400715 | A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas |
| Q37345350 | A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. |
| Q33282550 | A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin |
| Q46342158 | A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer |
| Q33783647 | AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association |
| Q30414737 | Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer |
| Q38459890 | Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study |
| Q30987695 | Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base |
| Q34755528 | Adenocarcinoma of the duodenum: factors influencing long-term survival |
| Q36681046 | Adenocarcinoma of the pancreas: A multimodality approach—A single surgeon's experience (1979—1988) |
| Q45854824 | Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments] |
| Q37797329 | Adjuvant Chemoradiation Therapy for Pancreas Cancer: Who Really Benefits? |
| Q81518436 | Adjuvant EBRT improves survival in patients with lymph-node-negative pancreatic cancer |
| Q34334926 | Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study |
| Q85106914 | Adjuvant Radiation Therapy for Distal Pancreatic Cancer: Is There a Role? |
| Q40474199 | Adjuvant Therapy with Chemotherapy and Radiation Therapy in the Management of Carcinoma of the Pancreatic Head |
| Q36563661 | Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer |
| Q37191059 | Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma |
| Q38736437 | Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials. |
| Q34370255 | Adjuvant and neoadjuvant therapies of pancreatic cancer: a review |
| Q35886631 | Adjuvant and neoadjuvant treatment in pancreatic cancer |
| Q33735469 | Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study |
| Q33820788 | Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? |
| Q46965913 | Adjuvant chemoradiation for patients with adenocarcinoma of the pancreas: an expirence of single institute |
| Q64988849 | Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. |
| Q33733149 | Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma |
| Q36579942 | Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas |
| Q34205488 | Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? |
| Q36979093 | Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater |
| Q36579200 | Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas |
| Q43804989 | Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial |
| Q34398248 | Adjuvant chemoradiotherapy for resected pancreas cancer |
| Q64280213 | Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer |
| Q41451390 | Adjuvant chemotherapy in pancreatic cancer |
| Q70655757 | Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study |
| Q33989437 | Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). |
| Q70880725 | Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth |
| Q38075827 | Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer |
| Q89579777 | Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail |
| Q45863331 | Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis |
| Q73705732 | Adjuvant radiation therapy for pancreatic cancer: a 15-year experience |
| Q35851281 | Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. |
| Q34506417 | Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group |
| Q55401908 | Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy. |
| Q73308572 | Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer |
| Q51170796 | Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. |
| Q30580152 | Adjuvant radiotherapy and lymph node status for pancreatic cancer: results of a study from the Surveillance, Epidemiology, and End Results (SEER) Registry Data |
| Q60692455 | Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients |
| Q37333663 | Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials? |
| Q37718744 | Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis |
| Q37210948 | Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress |
| Q38034110 | Adjuvant therapy for pancreas adenocarcinoma. |
| Q34259704 | Adjuvant therapy for pancreatic adenocarcinoma |
| Q35162483 | Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? |
| Q64069471 | Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database |
| Q72247648 | Adjuvant therapy for pancreatic cancer |
| Q37020384 | Adjuvant therapy for pancreatic cancer: a review |
| Q34311364 | Adjuvant therapy for pancreatic cancer: current treatment approaches and future challenges |
| Q79633834 | Adjuvant therapy for pancreatic cancer: the glass is half empty |
| Q24186323 | Adjuvant therapy for resected pancreatic cancer |
| Q94327146 | Adjuvant therapy for resected pancreatic cancer |
| Q34405072 | Adjuvant therapy in pancreatic cancer |
| Q77574356 | Adjuvant therapy in pancreatic cancer |
| Q36993370 | Adjuvant therapy in pancreatic cancer: a critical appraisal |
| Q64245397 | Adjuvant treatment for pancreatic cancer |
| Q37937922 | Adjuvant treatment of pancreatic cancer |
| Q36504334 | Adjuvant treatment strategies for pancreatic cancer |
| Q41828307 | Adjuvant treatment. |
| Q37287334 | Adjuvant treatments for resectable pancreatic cancer |
| Q38137541 | Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis |
| Q36400058 | Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer |
| Q37681300 | Advanced pancreatic carcinoma: current treatment and future challenges |
| Q40485489 | Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer |
| Q37495626 | Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies |
| Q35173639 | Alterations of ghrelin with weights and correlation among ghrelin, cytokine and survival in patients receiving chemoradiotherapy for gastrointestinal cancers |
| Q90618621 | An update on treatment options for pancreatic adenocarcinoma |
| Q87424507 | Analysis of dysregulation of immune system in pancreatic cancer based on gene expression profile |
| Q36572889 | Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital |
| Q37258944 | Approaches to localized pancreatic cancer |
| Q39430849 | Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma |
| Q39262474 | Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma |
| Q44562975 | Bayesian analysis unravels pancreas-cancer adjuvant therapy. |
| Q51273044 | Beam angle selection for intensity-modulated radiotherapy (IMRT) treatment of unresectable pancreatic cancer: are noncoplanar beam angles necessary? |
| Q37356861 | Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis |
| Q49711742 | Biliary Obstruction: Endoscopic Approaches |
| Q34649019 | Biology and management of pancreatic cancer |
| Q30772818 | Butylamino-demethoxy-hypocrellins and photodynamic therapy decreases human cancer in vitro and in vivo |
| Q73246587 | Carcinoma of the Pancreas |
| Q43676180 | Celiac artery adjuvant chemotherapy. Results of a prospective trial |
| Q35583949 | Chemoradiation in pancreatic adenocarcinoma: a literature review |
| Q44546852 | Chemoradiation in pancreatic carcinoma |
| Q37854733 | Chemoradiation therapy in the management of gastrointestinal malignancies |
| Q26746031 | Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? |
| Q33914136 | Chemoradiotherapy in pancreatic carcinoma |
| Q35095369 | Chemotherapeutic advances in pancreatic cancer |
| Q55000756 | Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. |
| Q39475203 | Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region |
| Q37086658 | Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer |
| Q35881178 | Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 × 5 Gy) and intraoperative radiation therapy (15 Gy) in patients with primarily resectable pancreatic cancer - NEOPANC |
| Q43560367 | Clinical significance of portal invasion by pancreatic head carcinoma |
| Q37458284 | Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement |
| Q37996462 | Combined modality treatments in pancreatic cancer |
| Q53527669 | Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. |
| Q79947506 | Comment on "adjuvant therapy in pancreatic cancer: a critical appraisal" |
| Q37011950 | Comment on "adjuvant therapy in pancreatic cancer: a critical appraisal". |
| Q46728458 | Complete response of a pancreatic adenosquamous carcinoma to chemoradiotherapy |
| Q34081281 | Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma |
| Q37487167 | Consensus on the treatment of pancreatic cancer in Spain. |
| Q43804982 | Continuing controversy over adjuvant therapy of pancreatic cancer |
| Q36820133 | Controversial issues in the management of pancreatic cancer: Part Two. A debate held at St Mary's Hospital, London on 18 November 1993. |
| Q41816674 | Controversies in the adjuvant treatment of pancreas cancer: a lack of knowledge or simply a lack of will? |
| Q44617854 | Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement |
| Q40474185 | Curative Treatment for Pancreatic Neoplasms: Standard Resection |
| Q52628886 | Current Concepts in the Treatment of Resectable Pancreatic Cancer. |
| Q38321245 | Current adjuvant therapeutic approaches for pancreatic cancer |
| Q34129346 | Current and emerging therapies for the treatment of pancreatic cancer. |
| Q41619954 | Current and emerging treatments for pancreatic cancer |
| Q34590796 | Current and future strategies for combined-modality therapy in pancreatic cancer |
| Q35149297 | Current approaches to novel therapeutics in pancreatic cancer |
| Q35925293 | Current standards of surgery for pancreatic cancer. |
| Q36425150 | Current state of adjuvant therapy in resected pancreatic adenocarcinoma |
| Q35583760 | Current status of adjuvant therapy for pancreatic cancer |
| Q37864970 | Current treatment options for pancreatic carcinoma |
| Q36528742 | Current treatment strategies for pancreatic cancer in the elderly |
| Q40729761 | Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. |
| Q57149093 | Defining the role of adjuvant external beam radiotherapy on resected adenocarcinoma of the ampulla of vater |
| Q37848744 | Development of pancreatoduodenectomy in North America |
| Q39434638 | Diagnostic evaluation of simulation CT images for adjuvant radiotherapy in pancreatic adenocarcinoma |
| Q61445866 | Dissected peripancreatic tissue margin is a critical prognostic factor and is associated with a gene mutation in pancreatic ductal adenocarcinoma |
| Q39980234 | Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis |
| Q40019138 | Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer |
| Q84563981 | Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation |
| Q37973133 | Drugs in preclinical and early-stage clinical development for pancreatic cancer. |
| Q33832655 | Ductal pancreatic adenocarcinoma |
| Q71105142 | Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy |
| Q36580127 | Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer |
| Q36462847 | Early vs. Late Chemoradiation Therapy and the Postoperative Interval to Adjuvant Therapy Do Not Correspond to Local Recurrence in Resected Pancreatic Cancer |
| Q38173993 | Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis |
| Q43594367 | Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas |
| Q70256099 | Effectiveness of multimodality treatment for resectable pancreatic cancer |
| Q46991076 | Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. |
| Q39504515 | Electron beam intraoperative radiation therapy (EBIORT) for localized pancreatic carcinoma |
| Q35779283 | Emerging drugs in pancreatic cancer |
| Q90062349 | Environmental Risk Factors of Pancreatic Cancer |
| Q50221174 | Essential role of radiation therapy for the treatment of pancreatic cancer : Novel study concepts and established treatment recommendations |
| Q35860636 | Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence |
| Q36678105 | Evaluating the role of photodynamic therapy in the management of pancreatic cancer |
| Q57846182 | Evaluation of Preoperative Therapy for Pancreatic Cancer Using a Prognostic Nomogram |
| Q35477482 | Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study |
| Q45168571 | Evidence of effective multidisciplinary treatment for resectable pancreatic cancer from the viewpoint of the CA19-9 level |
| Q38907389 | Evolution of novel therapeutic options for pancreatic cancer. |
| Q38624806 | Evolving treatment landscape for early and advanced pancreatic cancer |
| Q47624692 | Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. |
| Q39419609 | Factors influencing receipt of adjuvant chemotherapy after surgery for pancreatic cancer: a two-center retrospective cohort study |
| Q40743146 | Factors influencing survival after resection for periampullary neoplasms |
| Q36120997 | Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes |
| Q44810563 | Fight against cancer of the exocrine pancreas: stagnation or progress? The point of view of the Fondation française de cancérologie digestive (FFCD) |
| Q33367266 | Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma |
| Q30422810 | Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial |
| Q43567352 | Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas |
| Q52193842 | Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. |
| Q36644302 | Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma |
| Q38287286 | Histological and Molecular Subclassification of Pancreatic and Nonpancreatic Periampullary Cancers: Implications for (Neo) Adjuvant Systemic Treatment |
| Q88570154 | Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation |
| Q39279983 | Image-Guided Stereotactic Radiosurgery for Locally Advanced Pancreatic Adenocarcinoma Results of First 85 Patients |
| Q37738706 | Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). |
| Q34774546 | Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base |
| Q36029954 | Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. |
| Q41491695 | Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma |
| Q36666606 | Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy |
| Q30148661 | Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution |
| Q31145431 | Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma |
| Q36879149 | Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma |
| Q41863407 | Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy. |
| Q69264399 | Improved hospital morbidity, mortality, and survival after the Whipple procedure |
| Q38263106 | Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods |
| Q46078043 | Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer: a United States population-based assessment |
| Q36400047 | Improving Survival of Pancreatic Cancer. What Have We Learnt? |
| Q64945228 | Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. |
| Q34354462 | Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells |
| Q40837628 | Influence of multimodality therapy on the management of pancreas carcinoma |
| Q40673519 | Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial |
| Q64974733 | Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins. |
| Q40612379 | Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival |
| Q54085358 | Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. |
| Q37258940 | Intensity-modulated radiation therapy for gastrointestinal tumors |
| Q42142077 | Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer |
| Q40344727 | Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up |
| Q35768008 | Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy |
| Q73287922 | Intraoperative and postoperative radiotherapy in pancreatic cancer |
| Q69057784 | Intraoperative electron beam therapy for unresectable cancer of the pancreas |
| Q37576549 | Intraoperative radiation therapy (IORT) in pancreatic cancer. |
| Q44803833 | Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer |
| Q39742095 | Intraoperative radiotherapy |
| Q34210470 | Intraoperative radiotherapy for gastrointestinal cancer |
| Q41016179 | Intraoperative radiotherapy for pancreatic carcinoma. Experimental and clinical studies |
| Q73904230 | Intraoperative radiotherapy in resected pancreatic cancer: feasibility and results |
| Q34152694 | Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data |
| Q72575174 | Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts |
| Q26795522 | Irreversible electroporation and the pancreas: What we know and where we are going? |
| Q90723494 | Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? |
| Q36483585 | Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question |
| Q47355025 | Is pancreatic cancer hopeless? |
| Q33961798 | Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma |
| Q37137013 | Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma? |
| Q42535666 | Is there a role for intraoperative radiation therapy in patients with resected pancreatic adenocarcinoma? |
| Q67660722 | Isolated perfusion of pancreas with mitomycin C |
| Q36575464 | Laparoscopic staging and surgical treatment of pancreatic cancer |
| Q36209760 | Late complication in patients undergoing pancreatic resection with intraoperative radiation therapy: gastrointestinal bleeding with occlusion of the portal system |
| Q52647510 | Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. |
| Q45346218 | Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma |
| Q43679518 | Long-term follow-up of twenty patients with adenocarcinoma of the pancreas: resection following combined modality therapy |
| Q34732306 | Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma |
| Q44886616 | Long-term survival after multimodality treatment for resectable pancreatic cancer |
| Q40573146 | Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? |
| Q36637079 | Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma |
| Q34229432 | Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study |
| Q36748415 | Management of carcinomas of the upper gastrointestinal tract. |
| Q26774639 | Management of pancreatic cancer in the elderly |
| Q40408243 | Management of pancreatic carcinoma. |
| Q37853768 | Management strategies in pancreatic cancer |
| Q37677864 | Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design |
| Q36640493 | Meta-analyses of treatment standards for pancreatic cancer |
| Q36616676 | Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer |
| Q57795874 | Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone |
| Q93090259 | Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities |
| Q35834208 | Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma |
| Q40600706 | Modern surgical treatment of pancreatic cancer |
| Q34745252 | Molecular characteristics of pancreatic ductal adenocarcinoma |
| Q38062492 | Multidisciplinary management of locally advanced-borderline resectable adenocarcinoma of the head of the pancreas |
| Q37300020 | Multidisciplinary management of resectable adenocarcinoma of the pancreatic head |
| Q36023889 | Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer |
| Q70393520 | Multidisciplinary treatment for resectable pancreatic cancer |
| Q38838167 | Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. |
| Q43893210 | Neo-adjuvant and adjuvant treatments of pancreatic cancer |
| Q38979712 | Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets |
| Q36347277 | Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma. |
| Q58611183 | Neoadjuvant and adjuvant chemotherapy in pancreatic cancer |
| Q41690629 | Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. |
| Q47750487 | Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection |
| Q36253159 | Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma |
| Q35076334 | Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma |
| Q33751263 | Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives |
| Q26799428 | Neoadjuvant therapy for localized pancreatic cancer: guiding principles |
| Q27004292 | Neoadjuvant therapy for pancreas cancer: past lessons and future therapies |
| Q37079868 | Neoadjuvant therapy for pancreatic cancer |
| Q37699137 | Neoadjuvant therapy for pancreatic cancer: a current review |
| Q41826893 | Neoadjuvant therapy for pancreatic cancer: an ongoing debate |
| Q33775311 | Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies |
| Q33914671 | Neoadjuvant therapy in pancreatic cancer: an emerging strategy |
| Q46411105 | Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma |
| Q42408046 | Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? |
| Q28082422 | New challenges in perioperative management of pancreatic cancer |
| Q34042060 | New directions in systemic therapy of pancreatic cancer |
| Q71821843 | New versus old: Pancreatic cancer and chemoradiation attempts |
| Q55406377 | Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment. |
| Q26799425 | Novel adjuvant therapies for pancreatic adenocarcinoma |
| Q34259710 | Novel approaches to postoperative chemoradiation therapy in pancreatic cancer |
| Q38357201 | Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. |
| Q35196553 | Novel gene therapy approaches to pancreatic cancer |
| Q34074879 | Novel non-operative treatment and treatment strategies in pancreatic cancer |
| Q35687705 | Old and new drugs in systemic therapy of pancreatic cancer |
| Q79955539 | On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer |
| Q80016550 | Oncological problems in pancreatic cancer surgery |
| Q39240683 | Oncolytic viral therapy for pancreatic cancer. |
| Q34311344 | Opinions and commentary on treating pancreatic cancer |
| Q45735746 | Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis |
| Q37076542 | Optimal adjuvant therapy for resected pancreatic cancer: chemotherapy or chemoradiotherapy? |
| Q39245474 | Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity |
| Q57810991 | Optimizing the outcomes of pancreatic cancer surgery |
| Q34331762 | Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma |
| Q33947839 | Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas |
| Q38044710 | Outcomes following resection of pancreatic cancer. |
| Q47155379 | Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy |
| Q36062611 | Outcomes of resected pancreatic cancer in patients age ≥70. |
| Q37785591 | Overview of chemotherapy for pancreatic cancer |
| Q73931463 | Palliative and adjuvant regional chemotherapy in pancreatic cancer |
| Q60922849 | Pancreas cancer, careful improvements and human connections |
| Q54135367 | Pancreatic Cancer |
| Q44637031 | Pancreatic Cancer Cell DNA Content Correlates With Long-term Survival After Pancreatoduodenectomy |
| Q26743482 | Pancreatic Cancer from Molecular Pathways to Treatment Opinion |
| Q64991061 | Pancreatic Cancer: Feasibility and Outcome After Radiochemotherapy with High Dose External Radiotherapy for Non-resected and R1 Resected Patients. |
| Q39390859 | Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies |
| Q34140498 | Pancreatic adenocarcinoma |
| Q71746934 | Pancreatic adenocarcinoma |
| Q30470412 | Pancreatic adenocarcinoma in the pregnant patient: case report and review of the literature |
| Q24170403 | Pancreatic cancer |
| Q29622871 | Pancreatic cancer |
| Q42786282 | Pancreatic cancer |
| Q74267140 | Pancreatic cancer |
| Q36863139 | Pancreatic cancer and comparison of a hospital-based tumor registry with a National Cancer Data Base |
| Q26747524 | Pancreatic cancer from bench to bedside: molecular pathways and treatment options |
| Q38194599 | Pancreatic cancer in 1988. Possibilities and probabilities |
| Q26781555 | Pancreatic cancer surgery: past, present, and future |
| Q37779912 | Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning |
| Q51469668 | Pancreatic cancer: Is it time for Dr Whipple's orphans to have a Facebook page? |
| Q74128072 | Pancreatic cancer: a current overview |
| Q38396634 | Pancreatic cancer: from state-of-the-art treatments to promising novel therapies |
| Q33749460 | Pancreatic cancer: pathobiology, treatment options, and drug delivery |
| Q30250026 | Pancreatic cancer: yesterday, today and tomorrow. |
| Q41016168 | Pancreatic carcinoma in perspective. A continuing challenge |
| Q41098165 | Pancreatic nodal metastases: biologic significance and therapeutic considerations. |
| Q69505043 | Pancreatic resection for pancreatic cancer |
| Q34722637 | Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients |
| Q50950502 | Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. |
| Q37153300 | Particle radiation therapy for gastrointestinal malignancies |
| Q34493969 | Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer |
| Q53580027 | Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. |
| Q83180835 | Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings |
| Q26801411 | Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma |
| Q36408362 | Perioperative transfusion for pancreaticoduodenectomy and its impact on prognosis in resected pancreatic ductal adenocarcinoma. |
| Q34311328 | Personal observations, opinions, and approaches to cancer of the pancreas and the periampullary area |
| Q56899396 | Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma |
| Q43694233 | Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas |
| Q34847994 | Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin |
| Q40579509 | Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy |
| Q73251655 | Pilot study of continuous-infusion 5-fluorouracil, oral leucovorin, and upper-abdominal radiation therapy in patients with locally advanced residual or recurrent upper gastrointestinal or extrapelvic colon cancer |
| Q34559465 | Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness |
| Q92258093 | Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer |
| Q44493051 | Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study |
| Q38030455 | Postoperative radiotherapy in periampullary cancers: a brief review |
| Q34600819 | Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704 |
| Q55274465 | Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. |
| Q78023541 | Practical recommendations for the management of adenocarcinoma of the pancreas |
| Q41016231 | Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma |
| Q43829586 | Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. |
| Q36011003 | Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer |
| Q40433832 | Preoperative chemoradiation for adenocarcinoma of the pancreas: Excessive toxicity of prophylactic hepatic irradiation |
| Q40712849 | Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas |
| Q37510393 | Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. |
| Q74220828 | Preoperative chemoradiation therapy for pancreatic cancer |
| Q40961807 | Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head |
| Q41016175 | Preoperative chemoradiotherapy for localized pancreatic carcinoma. A perspective |
| Q40527957 | Preoperative combined modality therapy for pancreatic cancer |
| Q43585242 | Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein |
| Q36668274 | Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. |
| Q69630435 | Primary cancer of the pancreas: a surgical enigma |
| Q33276956 | Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplina |
| Q37543165 | Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma |
| Q46395249 | Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients |
| Q53727950 | Prognostic indicators for survival after resection of pancreatic adenocarcinoma. |
| Q35430053 | Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma |
| Q34097755 | Progress for resectable pancreatic [corrected] cancer?: a population-based assessment of US practices |
| Q53360478 | Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1). |
| Q46581683 | Prophylactic hepatic irradiation following curative resection of pancreatic cancer |
| Q33810863 | Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence |
| Q92756404 | Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic |
| Q90346450 | Proton beam radiotherapy for pancreas cancer |
| Q48925522 | Quality of life after adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled study |
| Q38765467 | RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4 |
| Q46600345 | Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma |
| Q48457848 | Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer |
| Q33862744 | Radiation Therapy and 5-Fluorouracil in Pancreatic Cancer |
| Q71868292 | Radiation dose-response of human tumors |
| Q33349266 | Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas |
| Q33339757 | Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer |
| Q93050532 | Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy |
| Q81562848 | Radiation therapy improves survival in patients with pancreatic adenocarcinoma |
| Q31132302 | Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data |
| Q67665480 | Radical pancreatectomy for pancreatic cancer in the elderly. Is it safe and justified? |
| Q50872323 | Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. |
| Q37403232 | Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents. |
| Q90665403 | Radiotherapy as an Adjunct to Surgery for Pancreatic Cancer: Where Are We After More Than 30 Years of Research and Trials? |
| Q45052957 | Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis |
| Q34002121 | Radiotherapy in the Treatment of Patients With Unresectable Extrahepatic Cholangiocarcinoma |
| Q37989158 | Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful? |
| Q36635178 | Radiotherapy in the treatment of pancreatic cancer |
| Q34586257 | Randomized clinical trials in pancreatic cancer. |
| Q33389524 | Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma |
| Q24816432 | Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283]. |
| Q93721660 | Rare cancers and specialist centres |
| Q36419779 | Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma |
| Q33797364 | Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology |
| Q36569189 | Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology |
| Q24626346 | Recent progress in pancreatic cancer |
| Q80974176 | Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy |
| Q74604779 | Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome |
| Q40837666 | Relevance of quality of life assessment to the evaluation of combined-modality therapy |
| Q53618459 | Research gaps in pancreatic cancer research and comparative effectiveness research methodologies. |
| Q38180310 | Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter? |
| Q34221643 | Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators |
| Q40708413 | Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy |
| Q44145390 | Resection plus adjuvant chemotherapy improves survival in advanced pancreatic adenocarcinoma |
| Q37254976 | Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma |
| Q41451367 | Results of adjuvant therapy in resected pancreatic cancer |
| Q73508634 | Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma |
| Q35599597 | Review article: chemotherapy for pancreatic cancer. |
| Q40837209 | Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer. |
| Q30431857 | Review article: current treatment and optimal patient management in pancreatic cancer. |
| Q36058855 | Risk Factors Associated with Loco-Regional Failure after Surgical Resection in Patients with Resectable Pancreatic Cancer |
| Q41351063 | Role of Adjuvant Radiotherapy in Left-Sided Pancreatic Cancer-Population-Based Analysis with Propensity Score Matching |
| Q53027231 | Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. |
| Q36297522 | Role of adjuvant therapy in the management of pancreatic cancer |
| Q68750512 | Sequential high-dose methotrexate, 5-fluorouracil, and doxorubicin for treatment of advanced pancreatic cancer |
| Q33928253 | Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation |
| Q50854367 | Should pancreaticoduodenectomy be performed in octogenarians? |
| Q73810358 | Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes |
| Q60692463 | Stage-Specific Survival Differences Associated with Postoperative Radiotherapy for Gastrointestinal Cancers |
| Q46933631 | Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy |
| Q50860501 | Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. |
| Q34633359 | Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial |
| Q37579741 | Standardization of Surgical and Pathologic Variables is Needed in Multicenter Trials of Adjuvant Therapy for Pancreatic Cancer: Results from the ACOSOG Z5031 Trial |
| Q92055156 | Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma |
| Q33559203 | Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for a phase II study |
| Q55186246 | Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer after Prior Radiation. |
| Q55162030 | Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. |
| Q36231964 | Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas |
| Q38245676 | Stereotactic body radiation therapy in pancreatic cancer: the new frontier |
| Q46287652 | Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial |
| Q35641993 | Surgical management of early-stage pancreatic cancer |
| Q33953527 | Surgical management of hereditary pancreatic cancer |
| Q41669028 | Surgical morbidity, mortality, and long-term survival in patients with peripancreatic cancer following pancreaticoduodenectomy |
| Q58861522 | Surgical treatment of pancreatic adenocarcinoma using cephalic duodenopancreatectomy (Part 2). Long term follow up after 204 cases |
| Q37287916 | Surgical treatment of pancreatic cancer |
| Q57823419 | Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades |
| Q35971517 | Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? |
| Q37590242 | Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: an analysis of clinicopathological factors |
| Q37564830 | Survival benefits from postoperative radiation therapy on lymph node positive patients with pancreatic adenocarcinoma |
| Q47607338 | Survival following pancreatic carcinoma: a follow-up study of all cases recorded in Malmö, Sweden, 1977-1991. |
| Q37719839 | Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens |
| Q43594371 | Synthetic peptide YY analog binds to a cell membrane receptor and delivers fluorescent dye to pancreatic cancer cells |
| Q38204280 | TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. |
| Q34311335 | The Mayo clinic approach to the surgical treatment of adenocarcinoma of the pancreas |
| Q48599351 | The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. |
| Q36194657 | The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement |
| Q33699802 | The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience |
| Q41464318 | The art and science of radiation therapy for gastrointestinal cancers |
| Q36569129 | The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas |
| Q36710829 | The case for routine use of adjuvant therapy in pancreatic cancer |
| Q44445114 | The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma |
| Q39990997 | The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery |
| Q54471967 | The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer. |
| Q37522823 | The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma |
| Q34570963 | The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. |
| Q35021013 | The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. |
| Q93019033 | The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma |
| Q37054817 | The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis |
| Q36773130 | The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer |
| Q37140933 | The role of radiation therapy in pancreas cancer |
| Q37863639 | The role of radiation therapy in the control of locoregional and metastatic cancer |
| Q39308769 | The role of radiation therapy in treatment of pancreatic cancer from the viewpoint of radio-oncologists |
| Q36097189 | The role of radiotherapy in management of pancreatic cancer |
| Q34025910 | The role of radiotherapy in multimodal treatment of pancreatic carcinoma |
| Q77422077 | The role of radiotherapy in the surgical management of gastrointestinal cancer |
| Q65002154 | The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. |
| Q64104622 | The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma |
| Q74019832 | The treatment of locally advanced pancreatic carcinoma--a dual challenge |
| Q71131895 | The use of spiral computed tomography in the evaluation of vessel encasement for pancreatic cancer |
| Q60609561 | Therapeutic developments in pancreatic cancer: current and future perspectives |
| Q37945640 | Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients |
| Q67991330 | Three-dimensional dosimetric comparison of radiation therapy treatment planning of the pancreas |
| Q33905392 | Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma |
| Q38926612 | Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma |
| Q51196995 | Treatment of borderline resectable pancreatic cancer. |
| Q81214786 | Treatment of familial pancreatic cancer and its precursors |
| Q51554445 | Treatment of locoregional disease: adjuvant versus neoadjuvant. |
| Q47680946 | Treatment of pancreatic cancer: challenge of the facts |
| Q34042055 | Treatment of resectable and locally advanced pancreatic cancer |
| Q51772050 | Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. |
| Q80800372 | Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study |
| Q34062486 | Trends in the treatment of resectable pancreatic adenocarcinoma |
| Q35603860 | Trends in the use of pre-operative radiation for adenocarcinoma of the pancreas in the United States |
| Q67672610 | Ultrasonically guided percutaneous implantation of iodine-125 seeds in pancreatic carcinoma |
| Q36095529 | Update on the Management of Pancreatic Cancer in Older Adults |
| Q28087060 | Update on the management of pancreatic cancer: surgery is not enough |
| Q37183479 | Upper gastrointestinal tumors: current status and future perspectives |
| Q63865739 | Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse. |
| Q79522368 | Use of adjuvant radiotherapy at hospitals with and without on-site radiation services |
| Q37330175 | Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer |
| Q40580320 | Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival |
| Q37002603 | Validation of a prognostic nomogram in patients undergoing resection for pancreatic ductal adenocarcinoma in a UK tertiary referral centre |
| Q34182126 | Validation of group B borderline resectable pancreatic cancer: retrospective analysis |
| Q55119439 | Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. |
| Q26774641 | Viro-immune therapy: A new strategy for treatment of pancreatic cancer |
| Q39060622 | When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma |
| Q73085267 | [Adenocarcinoma of the exocrine pancreas: management and therapeutic hopes] |
| Q74349154 | [Concomitant chemoradiotherapy and preoperative radiotherapy in exocrine pancreatic adenocarcinoma] |
| Q77919354 | [Concomitant chemoradiotherapy in the therapeutic strategy of adenocarcinoma of the exocrine pancreas and stomach] |
| Q81290494 | [How to improve treatment of resectable pancreatic adenocarcinomas? Surgical resection, histopathological examination, adjuvant therapies] |
| Q74547689 | [Role of adjuvant chemoradiotherapy in the therapeutic strategy of exocrine adenocarcinoma of the pancreas] |
| Q52975244 | [Therapy of pancreatic adenocarcinoma]. |
| Q33727842 | dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial |
Search more.